

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/080397 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 487/04**,  
A61K 31/4188, A61P 1/00

L4V 1V7 (CA). **MCLEOD, Donald** [US/US]; c/o NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, UT 84108 (US). **XIN, Tao** [CA/CA]; 10 Comoq Avenue, Woodbridge, Ontario L4H 2B1 (CA).

(21) International Application Number:  
PCT/US2005/005218

(74) Agents: **MEIKLE, Andrew, Duff** et al.; Birch, Stewart, Kolasch & Birch, LLP, 8110 Gatehouse Road, Suite 100 East, P.O. Box 747, Falls Church, VA 22040-0747 (US).

(22) International Filing Date: 17 February 2005 (17.02.2005)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

**Published:**

(30) Priority Data:  
60/545,580 19 February 2004 (19.02.2004) US

— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(71) Applicants (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE). **NPS PHARMACEUTICALS, INC.** [US/US]; 383 Colorow Drive, Salt Lake City, UT 84108 (US).

(88) Date of publication of the international search report:  
22 December 2005

(72) Inventors; and  
(75) Inventors/Applicants (for US only): **JOHANSSON, Martin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **WENSBO, David** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **MINIDIS, Alexander** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **STAAF, Karin** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **KERS, Annika** [SE/SE]; c/o AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **EDWARDS, Louise** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **ISAAC, Methvin** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **STEFANAC, Tomislav** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **SLASSI, Abdelmalik** [CA/CA]; c/o NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



(57) Abstract: The present invention is directed to compounds of formula: (I); wherein X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, X<sup>7</sup>, X<sup>8</sup>, X<sup>9</sup>, X<sup>10</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds for treating gastrointestinal disorders.

WO 2005/080397 A3